Evidence map›Paper›PMID 41869320›Full record

ArticleFrontiers in immunology2026

Development and characterization of chimeric antigen receptor macrophages for amyloid clearance.

Manasi Balachandran, James S Foster, Trevor J Hancock, Emily B Martin, Joseph W Jackson, Nicolas Angell, Jonathan S Wall

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manasi BalachandranDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.
James S FosterDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.
Trevor J HancockDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.
Emily B MartinDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.
Joseph W JacksonDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.
Nicolas AngellAttralus Inc., Naples, FL, United States.
Jonathan S WallDepartment of Medicine, University of Tennessee Health Science Center, College of Medicine, Knoxville, TN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic amyloidosis is a protein folding disorder characterized by the extracellular deposition of protein fibrils in tissues and vital organs, leading to dysfunction and mortality. While there are monoclonal antibody-based therapies that promote cell-mediated amyloid clearance in various stages of clinical development, there are currently no treatment options which focus on reducing the tissue amyloid burden. Therefore, the urgent need for a transformative approach to facilitate amyloid clearance and restore organ function remains paramount. We demonstrate that a short, polybasic peptide (p5) can serve as a versatile recognition motif for chimeric antigen receptors in macrophages, enabling pan-amyloid binding and uptake. By comparing CH2- and CH3-spacer designs, quantifying glycan interactions, and establishing opsonization- and complement-dependent enhancement, we provide a blueprint for peptide-targeted CAR-M engineering beyond conventional scFv recognition. These findings broaden the repertoire of CAR targeting strategies and motivate translational studies of CAR-M for systemic amyloidosis, where established fibrils persist despite precursor-lowering therapies.

Indexed as

AmyloidAmyloidosisMacrophagesReceptors, Chimeric AntigenAnimalsHumansMicePhagocytosisAmyloidReceptors, Chimeric Antigenamyloidosischimeric antigen receptormacrophagesphagocytosispolybasic peptides

Identifiers

PMID41869320
PMCPMC13002434

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.